Oncotarget

Oncotarget

Spotlight

This week, Oncotarget announced that its peer-reviewed research publications will be indexed in Meta, a world-renowned database of scientific literature, alongside other Impact Journal publications. Meta was acquired by the Chan Zuckerberg Initiative in an effort to make Meta's artificial intelligence (AI) technologies available to enhance scientists' ability to search, read, and tie together millions of scientific papers.
https://www.prnewswire.com/news-releases/oncotarget-to-be-indexed-in-highly-esteemed-meta-database-300601748.html?tc=eml_cleartime

Due to its rising importance, impact, volume and quality, Oncotarget will begin publishing two issues per week on Tuesday and Friday.
To accelerate dissemination of highly important scientific information, all accepted papers will be included directly into final paginated issues to be released to PubMed quickly and in their permanent form.
The entire Volume 8 is now in PubMed.
Issues 9(1-5) are now in PubMed. Please see the link.
Issues 9(6-9) are currently submitted and are being processed by the National Library of Medicine to appear in PubMed.

New Impact factor (IF) is 5.168

Title IF
e-Life 7.725
Oncogene 7.519
Oncotarget 5.168
Mol Cell Biol 4.398
Sci Reports 4.259
JBC 4.125
BMC Cancer 3.288
PLOS ONE 2.806

According to a statement from MEDLINE on 6/22/2017,
"This journal continues to play a major role in the publication of important basic science research papers. Editorial practices are consistently high. Ethical guidelines are consistently followed. This is an important research journal for the field."

Featured articles by DR Lowy, the acting director of the NCI (2015-2017):
DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers. Wang D, Qian X, Rajaram M, Durkin ME, Lowy DR.
Oncotarget. 2016 Jul 19;7(29):45144-45157.
DLC1: a tumor suppressor that regulates Rho signaling. Tripathi BK, Lowy DR.
Oncotarget. 2017 Apr 25;8(17):27674-27675.

Impact factor (IF) Web of Science (Clarivate Analytics)

Year IF Total Cites
2016 5.168 30241
2015 5.008 10452
2014 6.359 3908
2013 6.627 2217
2012 6.636 1450
2011 4.784 493

In October of 2017, Clarivate Analytics, (owner of the Web of Science index) honored Oncotarget as one of the 14 “rising star” journals for 2017.

We remain perplexed by their abrupt decision not to include Oncotarget in the master list of journals for 2018 without provided advanced notice or clear grounds. We are actively working to understand and rectify the situation.

The term "Oncotarget" encompasses all molecules, pathways, and cellular processes common in cancer and aging, which include neurodegeneration, atherosclerosis, lymphocytes, neurons, cancer cells and microbes.

2015/2016: 5-Year Impact Factor: 5.415

Scopus/SJR ranking: 2011-ongoing: Q1 (highest rank). All years Q1 in Medicine and Oncology (subject area).

Oncotarget ranks number 1 on Total Documents (2015-2016) among all journals in Oncology, see here

Oncotarget is an outstanding and most important journal in the field of oncology and cancer research. Oncotarget is performing an extremely useful function for those of us working not only in cancer research, but also on other important topics in the field of medicine. Oncotarget deserves a strong support from investigators working in the area of oncology as well as from NIH.

-- Andrew V. Schally, member of the Editorial Board
Nobel Prize in Physiology or Medicine, 1977

Members of Editorial Board Carlo M. Croce (former Editor-in-Chief of Cancer Research) and Andrew Schally (Nobel Prize winner) have respectively published 27 and 10 papers in Oncotarget.

250 Plus Papers from the Editorial Board:
See full list



Copyright © 2018 Impact Journals
Impact Journals is a registered trademark of Impact Journals, LLC